Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

A dive into the ASH 2018 abstracts highlights cancer metabolism as a top focus
BioCentury | Sep 10, 2018
Distillery Therapeutics

Cancer

BioCentury | Mar 21, 2017
Distillery Therapeutics

Gastrointestinal

BioCentury | Mar 9, 2017
Product R&D

Double your pleasure

SignalRx designing dual and triple inhibitors in silico
BioCentury | Jan 18, 2016
Company News

Tensha Therapeutics, Roche deal

BioCentury | Jan 12, 2016
Company News

Roche BETs on Tensha

BioCentury | Oct 8, 2015
Distillery Therapeutics

Therapeutics: β-catenin (CTNNB1); BET bromodomain proteins

Items per page:
1 - 10 of 36